Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Phase 2

Not yet recruiting

Conditions: Colon Cancer
Rectal Cancer
Colorectal Cancer
Colorectal Cancer (CRC)

Interventions: Drug: fruquintinib
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

First Posted Date: 2025-06-09

Last Posted Date: 2025-06-15

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT07011576

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma, Newly Diagnosed
Multiple Myeloma (MM)

Interventions: Drug: Daratumumab
Drug: Elranatamab
Drug: Lenalidomide
Procedure: autologous stem cell transplantation

First Posted Date: 2025-05-16

Last Posted Date: 2025-06-25

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 100

Registration Number: NCT06974786

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Phase 2

Recruiting

Conditions: Limited Stage Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: BMS-986489

First Posted Date: 2025-01-14

Last Posted Date: 2025-06-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 250

Registration Number: NCT06773910

Locations: 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Ocala Oncology Center, Ocala, Florida, United States

and more 18 locations

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Teclistamab
Drug: Talquetamab
Drug: Tocilizumab

First Posted Date: 2023-08-02

Last Posted Date: 2025-05-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 75

Registration Number: NCT05972135

Locations: 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States

and more 13 locations

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Lorlatinib
Drug: Cisplatin or Carboplatin
Drug: Pemetrexed

First Posted Date: 2023-07-17

Last Posted Date: 2023-12-13

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT05948462

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Messino Cancer Center, Asheville, North Carolina, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 2 locations

Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucatinib
Drug: Doxil

First Posted Date: 2023-03-01

Last Posted Date: 2025-01-31

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 36

Registration Number: NCT05748834

Locations: 🇺🇸
Alliance Cancer Specialists, Bensalem, Pennsylvania, United States
🇺🇸
Maryland Oncology Hematology, Columbia, Maryland, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States

and more 5 locations

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer
Locally Advanced Breast Cancer

Interventions: Drug: U3-1402

First Posted Date: 2021-01-07

Last Posted Date: 2025-06-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 121

Registration Number: NCT04699630

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 8 locations

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2020-05-26

Last Posted Date: 2025-05-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 15

Registration Number: NCT04402138

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Tulane University, Office of Clinical Research, New Orleans, Louisiana, United States
🇺🇸
HCA Midwest, Kansas City, Missouri, United States

and more 1 locations

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Phase 1

Withdrawn

Conditions: Myelodysplastic Syndromes
Leukemia, Myeloid, Acute
Myelodysplastic Syndrome Acute Myeloid Leukemia

Interventions: Drug: Nivolumab

First Posted Date: 2020-04-24

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT04361058

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: CPX-351
Drug: Quizartinib

First Posted Date: 2019-12-24

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 1

Registration Number: NCT04209725

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
HCA Midwest, Kansas City, Missouri, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy